Matching articles for "menopause"

In Brief: New Warning for Fezolinetant (Veozah)

   
The Medical Letter on Drugs and Therapeutics • October 14, 2024;  (Issue 1713)
The FDA has required a new warning in the label of the oral selective neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah) about the risk of hepatoxicity. The label of fezolinetant, which was...
The FDA has required a new warning in the label of the oral selective neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah) about the risk of hepatoxicity. The label of fezolinetant, which was approved by the FDA in 2023 for treatment of moderate to severe vasomotor symptoms due to menopause, already contained a warning about hepatic transaminase elevations associated with use of the drug.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):168 | Show Full IntroductionHide Full Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • March 4, 2024;  (Issue 1697)
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 | Show Full IntroductionHide Full Introduction

Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • June 26, 2023;  (Issue 1679)
Fezolinetant (Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is...
Fezolinetant (Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is the second nonhormonal treatment to be approved in the US for this indication; a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle) was approved in 2013.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):97-9 | Show Full IntroductionHide Full Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • August 10, 2020;  (Issue 1604)
The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia,...
The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and dysuria, and increase the risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep. Hormone therapy is the most effective treatment for both genitourinary and vasomotor symptoms.
Med Lett Drugs Ther. 2020 Aug 10;62(1604):124-8 | Show Full IntroductionHide Full Introduction

Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • July 29, 2019;  (Issue 1577)
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and...
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and allow for more dosing flexibility.
Med Lett Drugs Ther. 2019 Jul 29;61(1577):120 | Show Full IntroductionHide Full Introduction

Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • July 1, 2019;  (Issue 1575)
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with...
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketing Bijuva as "the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule".
Med Lett Drugs Ther. 2019 Jul 1;61(1575):99-101 | Show Full IntroductionHide Full Introduction

Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia

   
The Medical Letter on Drugs and Therapeutics • September 10, 2018;  (Issue 1555)
The FDA has approved an estradiol softgel vaginal insert (Imvexxy – TherapeuticsMD) for treatment of postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy (VVA). Imvexxy is...
The FDA has approved an estradiol softgel vaginal insert (Imvexxy – TherapeuticsMD) for treatment of postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy (VVA). Imvexxy is the second estradiol vaginal insert to be approved in the US; Vagifem, an intravaginal tablet formulation, was the first. Vagifem and Imvexxy are both available in inserts containing 10 mcg of estradiol; Imvexxy is also available in a 4-mcg strength.
Med Lett Drugs Ther. 2018 Sep 10;60(1555):147-8 | Show Full IntroductionHide Full Introduction

Prasterone (Intrarosa) for Dyspareunia

   
The Medical Letter on Drugs and Therapeutics • September 11, 2017;  (Issue 1529)
The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called...
The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the adrenal glands, gonads, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA has been available over the counter for years as an oral dietary supplement claimed to benefit sexual, cardiovascular, and neuropsychiatric dysfunction.
Med Lett Drugs Ther. 2017 Sep 11;59(1529):149-50 | Show Full IntroductionHide Full Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • November 7, 2016;  (Issue 1507)
The primary symptoms of menopause are genitourinary and vasomotor. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar burning and irritation, pain during intercourse, and...
The primary symptoms of menopause are genitourinary and vasomotor. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar burning and irritation, pain during intercourse, and an increased risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep.
Med Lett Drugs Ther. 2016 Nov 7;58(1507):142-5 | Show Full IntroductionHide Full Introduction

Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms and Prevention of Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • April 28, 2014;  (Issue 1441)
The FDA has approved Duavee (Pfizer), a fixed-dose combination of conjugated estrogens and the new selective estrogen receptor modulator (SERM) bazedoxifene, for treatment of moderate to severe vasomotor...
The FDA has approved Duavee (Pfizer), a fixed-dose combination of conjugated estrogens and the new selective estrogen receptor modulator (SERM) bazedoxifene, for treatment of moderate to severe vasomotor symptoms and for prevention of osteoporosis in postmenopausal women with an intact uterus. Bazedoxifene is an estrogen agonist/antagonist with estrogen-like effects on bone and antiestrogen effects on the uterus. It is the second SERM to be approved for prevention of osteoporosis; raloxifene (Evista, and generics) has been available as a single agent for this indication since 1997.
Med Lett Drugs Ther. 2014 Apr 28;56(1441):33-4 | Show Full IntroductionHide Full Introduction

Paroxetine (Brisdelle) for Hot Flashes

   
The Medical Letter on Drugs and Therapeutics • October 28, 2013;  (Issue 1428)
The FDA has approved a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle – Noven Therapeutics) for treatment of moderate-to-severe vasomotor symptoms...
The FDA has approved a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle – Noven Therapeutics) for treatment of moderate-to-severe vasomotor symptoms associated with menopause. It is the first non-hormonal therapy to be approved for this indication. Paroxetine mesylate (Pexeva) and paroxetine hydrochloride (Paxil, and generics) are marketed in higher doses for treatment of depression and other psychiatric disorders.
Med Lett Drugs Ther. 2013 Oct 28;55(1428):85-6 | Show Full IntroductionHide Full Introduction

Ospemifene (Osphena) for Dyspareunia

   
The Medical Letter on Drugs and Therapeutics • July 8, 2013;  (Issue 1420)
The FDA has approved ospemifene (os pem’ i feen; Osphena – Shionogi), an estrogen agonist/antagonist, for oral treatment of moderate to severe dyspareunia in postmenopausal women. Ospemifene is the...
The FDA has approved ospemifene (os pem’ i feen; Osphena – Shionogi), an estrogen agonist/antagonist, for oral treatment of moderate to severe dyspareunia in postmenopausal women. Ospemifene is the fourth estrogen agonist/antagonist to be marketed in the US, but it is the only one that has an estrogen-like effect on vaginal epithelium. The other three, tamoxifen (Nolvadex, and generics), toremifene (Fareston), and raloxifene (Evista), are used for treatment and prevention of breast cancer and osteoporosis.
Med Lett Drugs Ther. 2013 Jul 8;55(1420):55-6 | Show Full IntroductionHide Full Introduction

Addendum: Transdermal Estrogen

   
The Medical Letter on Drugs and Therapeutics • July 9, 2012;  (Issue 1394)
A reader commented that our recent article on treatment of menopausal symptoms (Med Lett Drugs Ther 2012; 54:41) should have mentioned the potential advantages of transdermal estrogen. Transdermal estrogens are...
A reader commented that our recent article on treatment of menopausal symptoms (Med Lett Drugs Ther 2012; 54:41) should have mentioned the potential advantages of transdermal estrogen. Transdermal estrogens are probably as effective as oral estrogens in treating vasomotor menopausal symptoms, but transdermal administration may have less effect on serum triglycerides, C-reactive protein, thyroxine-binding globulin, cortisol-binding globulin and sex hormone-binding globulin. Observational data suggest that the risk of venous thromboembolism may be lower with transdermal administration compared to standard-dose oral estrogens, but comparative randomized controlled trials are lacking.

Download complete U.S. English article

Med Lett Drugs Ther. 2012 Jul 9;54(1394):56 | Show Full IntroductionHide Full Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • May 28, 2012;  (Issue 1391)
The primary symptoms of menopause are vasomotor and genitourinary. Vasomotor symptoms ("hot flashes") cause daytime discomfort and chronic insomnia. A thin, dry vaginal lining and thin urethral mucosa can...
The primary symptoms of menopause are vasomotor and genitourinary. Vasomotor symptoms ("hot flashes") cause daytime discomfort and chronic insomnia. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar irritation, pain during intercourse, and an increased risk for urinary tract infection.
Med Lett Drugs Ther. 2012 May 28;54(1391):41-3 | Show Full IntroductionHide Full Introduction

Drugs for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • November 1, 2011;  (Issue 111)
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by...
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone densitometry, which is generally reported in terms of standard deviations (SD) from mean values in young adults (T-score). The World Health Organization (WHO) has defined normal bone mineral density (BMD) for women as a value within one SD of the young adult mean. Values 2.5 SD or more below the mean (T score -2.5) are defined as osteoporosis. The WHO has developed a computerized model (FRAX) that predicts the 10-year probability of a hip fracture or any other major osteoporotic fracture based on clinical risk factors and BMD at the femoral neck.
Treat Guidel Med Lett. 2011 Nov;9(111):67-74 | Show Full IntroductionHide Full Introduction

Do Calcium Supplements Increase the Risk of Myocardial Infarction?

   
The Medical Letter on Drugs and Therapeutics • October 17, 2011;  (Issue 1375)
Supplemental calcium is recommended for prevention of postmenopausal osteoporosis in women with an inadequate dietary intake of calcium. The safety of calcium supplements has recently been...
Supplemental calcium is recommended for prevention of postmenopausal osteoporosis in women with an inadequate dietary intake of calcium. The safety of calcium supplements has recently been questioned; patients may ask if they should continue to take them. The source of this concern was the publication of 2 meta-analyses in the British Medical Journal.
Med Lett Drugs Ther. 2011 Oct 17;53(1375):83 | Show Full IntroductionHide Full Introduction

Drugs for Female Sexual Dysfunction

   
The Medical Letter on Drugs and Therapeutics • December 13, 2010;  (Issue 1353)
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become...
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.
Med Lett Drugs Ther. 2010 Dec 13;52(1353):100-2 | Show Full IntroductionHide Full Introduction

Bioidentical Hormones

   
The Medical Letter on Drugs and Therapeutics • May 31, 2010;  (Issue 1339)
In recent years, many women have become concerned about the safety of pharmaceutical replacement hormones for treatment of menopausal symptoms. “Bioidentical” hormone preparations, which are not approved...
In recent years, many women have become concerned about the safety of pharmaceutical replacement hormones for treatment of menopausal symptoms. “Bioidentical” hormone preparations, which are not approved by the FDA, are heavily promoted in popular books and on TV as alternatives; these are derivatives of soy or plant extracts, chemically modified to be structurally identical to endogenous hormones. Most FDA-approved single-entity hormones are also derivatives of soy or plant extracts and are structurally identical to hormones produced by the ovary.
Med Lett Drugs Ther. 2010 May 31;52(1339):43-4 | Show Full IntroductionHide Full Introduction

Conjugated Estrogens (Premarin) Vaginal Cream

   
The Medical Letter on Drugs and Therapeutics • February 23, 2009;  (Issue 1306)
An old conjugated estrogens vaginal cream (Premarin Vaginal Cream - Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy...
An old conjugated estrogens vaginal cream (Premarin Vaginal Cream - Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause. Synthetic conjugated estrogens A vaginal cream (Barr) has also been approved for this indication, but has not yet been marketed.
Med Lett Drugs Ther. 2009 Feb 23;51(1306):14-5 | Show Full IntroductionHide Full Introduction

Drugs for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • October 1, 2008;  (Issue 74)
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone...
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone densitometry, which is generally reported in terms of standard deviations (SD) from mean values in young adults (T score). The World Health Organization (WHO) has defined normal bone mineral density (BMD) for women as a value within one SD of the young adult mean. Values 2.5 SD (T score -2.5) or more below the mean are defined as osteoporosis. The WHO has developed a computerized model (FRAX) that predicts the 10-year probability of hip fracture based on clinical risk factors and BMD at the femoral neck.
Treat Guidel Med Lett. 2008 Oct;6(74):67-74 | Show Full IntroductionHide Full Introduction

Monthly Risedronate (Actonel) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • September 8, 2008;  (Issue 1294)
The bisphosphonate risedronate (Actonel - Procter & Gamble) was recently approved by the FDA in a 150- mg once-monthly oral tablet for prevention and treatment of postmenopausal osteoporosis. The drug is also...
The bisphosphonate risedronate (Actonel - Procter & Gamble) was recently approved by the FDA in a 150- mg once-monthly oral tablet for prevention and treatment of postmenopausal osteoporosis. The drug is also available for the same indication in 5-mg daily, 35-mg weekly and 75-mg twice-monthly tablets.
Med Lett Drugs Ther. 2008 Sep 8;50(1294):69-70 | Show Full IntroductionHide Full Introduction

Low-Dose Transdermal Estrogens

   
The Medical Letter on Drugs and Therapeutics • August 27, 2007;  (Issue 1268)
Three low-dose transdermal estrogens were recently approved by the FDA for treatment of menopausal vasomotor symptoms. Elestrin and Divigel are transdermal estradiol gels and Evamist is an estradiol spray....
Three low-dose transdermal estrogens were recently approved by the FDA for treatment of menopausal vasomotor symptoms. Elestrin and Divigel are transdermal estradiol gels and Evamist is an estradiol spray. Elestrin has been marketed in Europe since 1976.
Med Lett Drugs Ther. 2007 Aug 27;49(1268):71-2 | Show Full IntroductionHide Full Introduction

Angeliq for Treatment of Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • February 12, 2007;  (Issue 1254)
A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last...
A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last Medical Letter issue reviewing such devices,1 more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
Med Lett Drugs Ther. 2007 Feb 12;49(1254):15-6 | Show Full IntroductionHide Full Introduction

Drugs for Prevention and Treatment of Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • October 1, 2005;  (Issue 38)
Many drugs are now marketed for treatment of postmenopausal osteoporosis, but questions remain about their...
Many drugs are now marketed for treatment of postmenopausal osteoporosis, but questions remain about their use.
Treat Guidel Med Lett. 2005 Oct;3(38):69-74 | Show Full IntroductionHide Full Introduction

Treatment of Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • December 6, 2004;  (Issue 1197)
Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were...
Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were at increased risk for myocardial infarction, stroke, pulmonary emboli, deep vein thrombosis, breast cancer, and possibly dementia. Are there effective alternatives?
Med Lett Drugs Ther. 2004 Dec 6;46(1197):98-9 | Show Full IntroductionHide Full Introduction

Menostar - A Low-Dose Estrogen Patch for Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • August 30, 2004;  (Issue 1190)
The FDA has approved a new low-dose estrogen patch (Menostar - Berlex) for prevention of osteoporosis in postmenopausal women. Unlike other estrogen patches, it is not approved for treatment of hot flashes or...
The FDA has approved a new low-dose estrogen patch (Menostar - Berlex) for prevention of osteoporosis in postmenopausal women. Unlike other estrogen patches, it is not approved for treatment of hot flashes or other menopausal symptoms. Promotional material from the manufacturer suggests that this low dose of estrogen could prevent osteoporosis without some of the adverse effects of higher doses.
Med Lett Drugs Ther. 2004 Aug 30;46(1190):69-70 | Show Full IntroductionHide Full Introduction

Drugs for Prevention and Treatment of Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • November 1, 2002;  (Issue 3)
Many drugs are now marketed for treatment of post-menopausal osteoporosis (PD Delmas, Lancet 2002; 359:2018). Prevention of this disorder has been complicated by the news that hormone replacement therapy (HRT),...
Many drugs are now marketed for treatment of post-menopausal osteoporosis (PD Delmas, Lancet 2002; 359:2018). Prevention of this disorder has been complicated by the news that hormone replacement therapy (HRT), which many women have been taking to prevent osteoporosis, increases the incidence of coronary heart disease and that of breast cancer, stroke and pulmonary embolism as well (Medical Letter 2002; 44:78).
Treat Guidel Med Lett. 2002 Nov;0(3):13-8 | Show Full IntroductionHide Full Introduction

Calcium Supplements

   
The Medical Letter on Drugs and Therapeutics • April 3, 2000;  (Issue 1075)
Claims for the superiority of various calcium supplements are now appearing on television and in the print media. A high calcium intake combined with vitamin D can increase bone density and reduce the incidence...
Claims for the superiority of various calcium supplements are now appearing on television and in the print media. A high calcium intake combined with vitamin D can increase bone density and reduce the incidence of fractures in older women and probably also in men.
Med Lett Drugs Ther. 2000 Apr 3;42(1075):29-31 | Show Full IntroductionHide Full Introduction

A New Conjugated Estrogen

   
The Medical Letter on Drugs and Therapeutics • July 30, 1999;  (Issue 1058)
A new synthetic conjugated estrogen product (Cenestin - Duramed) was recently approved by the US Food and Drug Administration for treatment of vasomotor symptoms due to estrogen...
A new synthetic conjugated estrogen product (Cenestin - Duramed) was recently approved by the US Food and Drug Administration for treatment of vasomotor symptoms due to estrogen deficiency.
Med Lett Drugs Ther. 1999 Jul 30;41(1058):67-70 | Show Full IntroductionHide Full Introduction